• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients-A Systematic Review

by | Jul 27, 2024 | Publications

Pharmaceuticals (Basel). 2024 Jul 15;17(7):944. doi: 10.3390/ph17070944. ABSTRACT This systematic review examines the available clinical data on CD34+ cell mobilization, collection, and engraftment in multiple myeloma patients treated with the anti-CD38 monoclonal...

Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review

by | Jul 22, 2024 | Publications

Ann Med. 2024 Dec;56(1):2380301. doi: 10.1080/07853890.2024.2380301. Epub 2024 Jul 22. ABSTRACT BACKGROUND: Multiple myeloma is a malignant tumour of the blood in which abnormal proliferation of plasma cells leads to bone destruction, renal impairment, anaemia, and...

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence

by | Jul 21, 2024 | Publications

Br J Haematol. 2024 Jul 19. doi: 10.1111/bjh.19627. Online ahead of print. ABSTRACT The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide-refractory patients, which may limit the efficacy of...

Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003;101(9):3606-3614

by | Jul 11, 2024 | Publications

Blood. 2024 Jul 11;144(2):239. doi: 10.1182/blood.2024025274. NO ABSTRACT PMID:38990539 | DOI:10.1182/blood.2024025274

Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma

by | Jul 11, 2024 | Publications

J Palliat Med. 2024 Jul 11. doi: 10.1089/jpm.2023.0530. Online ahead of print. ABSTRACT Background: Prior studies reveal a lack of illness understanding and prognostic awareness among patients with hematological malignancies. We evaluated prognostic awareness and...

Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma

by | Jul 11, 2024 | Publications

Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-0117. Online ahead of print. ABSTRACT PURPOSE: TIGIT blockade in our ex vivo models of bone marrow (BM) reduced the number of malignant plasma cells (PCs) in only half of patients with multiple myeloma (MM)....
« Older Entries
Next Entries »

Recent Content

  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT